Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by PLITheOneon May 15, 2020 9:37am
133 Views
Post# 31032461

RE:My guess is the original CMC problems

RE:My guess is the original CMC problemsYes let’s not forget that it seems completely intentional that the CRL received in April 2018, when we were expecting a PUFD, wasn’t disclosed to investors so they could use it as a cram down a year later. It seems this is when the criminal minds of SALP became influential. This negligence assisted them in stealing this company from investors. Management, yes that includes reps from SALP on the board, instead of announcing a CRL chose to ignore their fiduciary duty and opted to announce that they had retracted the BLA themselves to address CMC requirements. Just 4 more check points required and the a team of CMC experts familiar with the FDA processes were hired to address it. That was over two years ago now. These new mindless cheerleaders were not around for this and show little knowledge of this company. Beware if considering any of their garage posted here as reasons to invest.  

GoBBs wrote: were likely far more complicated than we were told ... going back to PL's sugar coating of the issues and not disclosing they recieved the CRL. Complete incompetence...Now these new clowns have to finish it and who knows how capable they are. Again if you read the MD&A they do not provide clear language as to where they are with the submission and the FDA. They just say "we plan to submit", "we're working on" , COVID will delay blah blah ... Instead they could say, "we are ready to re-submit but need to complete a,b,c still ... but this quarter we have completed x,y and z ... they don't do much to instill confidence in them and so the stock will go down. Pretty amatuer ....


<< Previous
Bullboard Posts
Next >>